ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy

被引：31

作者：

Zaanan, Aziz ^{[1
,2
,3
,4
,5
]}

Dalban, Cecile ^{[6
]}

Emile, Jean-Francois ^{[7
,8
]}

Blons, Helene ^{[4
,9
]}

Flejou, Jean-Francois ^{[1
,2
,10
]}

Goumard, Claire ^{[1
,2
]}

Istanbullu, Melek ^{[1
,2
]}

Calmel, Claire ^{[1
,2
]}

Alhazmi, Khalid ^{[11
]}

Validire, Pierre ^{[12
]}

Louvet, Christophe ^{[13
]}

de Gramont, Aimery ^{[14
]}

Laurent-Puig, Pierre ^{[4
,5
,9
]}

Taieb, Julien ^{[3
,4
,5
]}

Praz, Francoise ^{[1
,2
]}

机构：

[1] St Antoine Res Ctr, INSERM, UMR S 938, F-75012 Paris, France

[2] Univ Paris 06, St Antoine Res Ctr, UMR S 938, F-75012 Paris, France

[3] Hop Europeen Georges Pompidou, AP HP, Dept Gastroenterol & Digest Oncol, Paris, France

[4] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[5] Hop Europeen Georges Pompidou, AP HP, Canc Res Personalized Med CARPEM, Paris, France

[6] Georges Francois Leclerc Ctr, Dept Biostat & Epidemiol, EA4184, Dijon, France

[7] Hop Ambroise Pare, AP HP, Dept Pathol, Boulogne, France

[8] Univ Versailles, EA4340, F-78000 Versailles, France

[9] Hop Europeen Georges Pompidou, AP HP, Dept Biol, Paris, France

[10] St Antoine Hosp, Dept Pathol, Paris, France

[11] Hop Europeen Georges Pompidou, AP HP, Dept Pathol, Paris, France

[12] Mutualiste Montsouris Inst, Dept Pathol, Paris, France

[13] Mutualiste Montsouris Inst, Dept Med Oncol, Paris, France

[14] St Antoine Hosp, AP HP, Dept Med Oncol, Paris, France

来源：

JOURNAL OF CANCER | 2014年 / 5卷 / 06期

关键词：

colon cancer; adjuvant FOLFOX; polymorphism; ERCC1; XRCC1; GSTP1; ADVANCED COLORECTAL-CANCER; COMBINATION CHEMOTHERAPY; GENETIC-POLYMORPHISM; DNA-REPAIR; LEUCOVORIN; 5-FLUOROURACIL; FLUOROURACIL; OXALIPLATIN/5-FLUOROURACIL; ENDONUCLEASE; CAPECITABINE;

D O I：

10.7150/jca.8594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: While single nucleotide polymorphisms (SNP) in genes involved in DNA repair or drug metabolism have been shown to influence survival of metastatic colon cancer patients treated with FOLFOX, data on adjuvant setting are scarce. Methods: This study evaluated the correlation between disease-free survival (DFS) of 210 unselected stage III colon cancer patients receiving FOLFOX chemotherapy, and ERCC1-118 (rs11615, c. 354T> C), XRCC1-399 (rs25487, c. 1196G> A) and GSTP1-105 (rs1695, c. 313A> G) polymorphisms. SNP were determined on tumor DNA using a PCR-based RFLP technique. Results: In univariate analysis, a trend towards longer DFS was observed for ERCC1 (C/T + T/T) versus (C/C) (HR= 2.29; p= 0.06), and XRCC1 (A/A) versus (G/G + G/A) (HR= 1.61; p= 0.16), but not for GSTP1 genotypes; a statistically significant p value was obtained when combining ERCC1 and XRCC1 favorable genotypes (0 versus >= 1 favorable genotypes, HR=2.42; p=0.02). After adjustment on tumor stage, lymph node ratio and differentiation grade, multivariate analysis showed that combining ERCC1 and XRCC1 genotypes gave a p value slightly above the threshold for statistical significance (HR=2.03; p=0.06), which was lower than for tumor stage, lymph node ratio or differentiation grade. Conclusion: The association of ERCC1 and XRCC1 polymorphisms may influence the prognosis of stage III colon cancer patients treated with FOLFOX adjuvant chemotherapy. Yet, these findings need to be confirmed in independent prospective studies.

引用

页码：425 / 432

页数：8

共 29 条

[1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].